Announcing the PARASOL Project: PROTEINURIA AND GFR AS CLINICAL TRIAL ENDPOINTS IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Published on December 20, 2023
Announcing the PARASOL Project: PROTEINURIA AND GFR AS CLINICAL TRIAL ENDPOINTS IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS

ISGD is collaborating in a multidisciplinary effort to tackle the urgent problem of developing quantitative models to support clinical trial design and surrogate endpoint evaluation in FSGS. On December 9 and 10, we met with an international group of researchers, clinicians, biostatisticians, regulators, and patients in Washington, DC to kick off the PARASOL project (Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis).

Continue reading on website
Other news

Episode 2: Kidney Week Micro-Interviews

November 22, 2023
In this episode of GN in Ten, Koyal and Kenar take the show on the road to Kidney Week to ask attendees about their favorite glomerular diseases. Listen closely for a surprise Shakespearean crossover!

New Era Act Introduced in Congress

December 22, 2023
We are thrilled to share that the New Era of Preventing End-Stage Kidney Disease Act (“New Era Act”), which ISGD has been advocating for in partnership with NephCure, has been officially introduced in this session of Congress. This legislation, introduced by Representatives Gus Bilirakis (R-FL) and Terri Sewell (D-AL), holds the potential for significant improvements in rare kidney disease (RKD) r